Jefferies valuates Bavarian Nordic's Covid-19 project

Following Bavarian Nordic's capital raising round for developing the company's Covid-19 vaccine, and its fiscal report presentation, financial analyst Jefferies is ready to start incorporating the value of the vaccine into its company valuation.

Photo: Bavarian Nordic / PR

Financial services company Jefferies now adds value to Bavarian Nordic's Covid-19 vaccine ABNCoV2 and valuates the developmental project, which was in-licensed from Adaptvac, at DKK 25 (USD 4.0) per share, according to a Friday note relating to Bavarian's financial report. According to Jefferies, this was pretty much what the analyst firm expected, especially since Bavarian had already presented its preliminary figures in January.

Even though Bavarian's Covid-19 vaccine is currently part of Jefferies' valuation of the share, Jefferies maintains its share target at DKK 270. The firm still recommends to "buy".

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs